AU2014281515B2 - Compositions and methods for treating skin - Google Patents
Compositions and methods for treating skin Download PDFInfo
- Publication number
- AU2014281515B2 AU2014281515B2 AU2014281515A AU2014281515A AU2014281515B2 AU 2014281515 B2 AU2014281515 B2 AU 2014281515B2 AU 2014281515 A AU2014281515 A AU 2014281515A AU 2014281515 A AU2014281515 A AU 2014281515A AU 2014281515 B2 AU2014281515 B2 AU 2014281515B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- nbds
- isolated
- use according
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 59
- 210000003491 skin Anatomy 0.000 claims abstract description 73
- 230000002500 effect on skin Effects 0.000 claims abstract description 59
- 210000003780 hair follicle Anatomy 0.000 claims abstract description 32
- 210000004027 cell Anatomy 0.000 claims description 216
- 210000004209 hair Anatomy 0.000 claims description 35
- 208000028990 Skin injury Diseases 0.000 claims description 32
- 210000001519 tissue Anatomy 0.000 claims description 32
- 208000027418 Wounds and injury Diseases 0.000 claims description 24
- 206010052428 Wound Diseases 0.000 claims description 20
- 230000009759 skin aging Effects 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 10
- 210000002510 keratinocyte Anatomy 0.000 claims description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 229920002674 hyaluronan Polymers 0.000 claims description 9
- 229960003160 hyaluronic acid Drugs 0.000 claims description 9
- 210000001732 sebaceous gland Anatomy 0.000 claims description 7
- 238000001356 surgical procedure Methods 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 210000004623 platelet-rich plasma Anatomy 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 5
- 108010073385 Fibrin Proteins 0.000 claims description 4
- 102000009123 Fibrin Human genes 0.000 claims description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 4
- 229950003499 fibrin Drugs 0.000 claims description 4
- 238000000684 flow cytometry Methods 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 239000004017 serum-free culture medium Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 13
- 210000002107 sheath cell Anatomy 0.000 abstract description 6
- 230000032683 aging Effects 0.000 description 21
- 238000004113 cell culture Methods 0.000 description 20
- 239000012228 culture supernatant Substances 0.000 description 19
- 230000001684 chronic effect Effects 0.000 description 18
- 102000008186 Collagen Human genes 0.000 description 15
- 108010035532 Collagen Proteins 0.000 description 15
- 229920001436 collagen Polymers 0.000 description 15
- 239000002537 cosmetic Substances 0.000 description 13
- 208000014674 injury Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 230000000391 smoking effect Effects 0.000 description 10
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 9
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- 206010040954 Skin wrinkling Diseases 0.000 description 9
- 238000001574 biopsy Methods 0.000 description 9
- 231100000241 scar Toxicity 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 229940126864 fibroblast growth factor Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000008733 trauma Effects 0.000 description 8
- 230000037303 wrinkles Effects 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 210000002744 extracellular matrix Anatomy 0.000 description 7
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 6
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229920002683 Glycosaminoglycan Polymers 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 6
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 6
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 102000013275 Somatomedins Human genes 0.000 description 6
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 229940100601 interleukin-6 Drugs 0.000 description 6
- 102000049853 macrophage stimulating protein Human genes 0.000 description 6
- 108010053292 macrophage stimulating protein Proteins 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 208000032544 Cicatrix Diseases 0.000 description 5
- 241000283073 Equus caballus Species 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010039710 Scleroderma Diseases 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 201000011486 lichen planus Diseases 0.000 description 5
- 206010025135 lupus erythematosus Diseases 0.000 description 5
- 210000002752 melanocyte Anatomy 0.000 description 5
- 230000037387 scars Effects 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000034656 Contusions Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000006862 enzymatic digestion Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- -1 human albumin) Chemical compound 0.000 description 4
- 230000037311 normal skin Effects 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 102100022464 5'-nucleotidase Human genes 0.000 description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 208000035484 Cellulite Diseases 0.000 description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 3
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 3
- 101000614436 Homo sapiens Keratin, type I cytoskeletal 14 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 102100025305 Integrin alpha-2 Human genes 0.000 description 3
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 3
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 3
- 101710123753 Parathyroid hormone-related protein Proteins 0.000 description 3
- 206010049752 Peau d'orange Diseases 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000036232 cellulite Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940059329 chondroitin sulfate Drugs 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 108010007093 dispase Proteins 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004918 root sheath Anatomy 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 210000001208 inner root sheath cell Anatomy 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000012090 serum-supplement Substances 0.000 description 2
- 238000007390 skin biopsy Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000007794 visualization technique Methods 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010062542 Arterial insufficiency Diseases 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010087999 Steryl-Sulfatase Proteins 0.000 description 1
- 102100038021 Steryl-sulfatase Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000007387 excisional biopsy Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 210000005195 occipital scalp Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004621 scanning probe microscopy Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940030990 tachosil Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940033618 tisseel Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0627—Hair cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/56—Fibrin; Thrombin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/80—Hyaluronan
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361836634P | 2013-06-18 | 2013-06-18 | |
| US61/836,634 | 2013-06-18 | ||
| PCT/US2014/043048 WO2014205142A1 (en) | 2013-06-18 | 2014-06-18 | Compositions and methods for treating skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014281515A1 AU2014281515A1 (en) | 2016-02-04 |
| AU2014281515B2 true AU2014281515B2 (en) | 2019-11-07 |
Family
ID=51162967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014281515A Ceased AU2014281515B2 (en) | 2013-06-18 | 2014-06-18 | Compositions and methods for treating skin |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160136206A1 (https=) |
| EP (1) | EP3010515A1 (https=) |
| JP (4) | JP6594301B2 (https=) |
| KR (2) | KR20210114545A (https=) |
| CN (2) | CN116716242A (https=) |
| AU (1) | AU2014281515B2 (https=) |
| BR (1) | BR112015031772B1 (https=) |
| CA (1) | CA2919091A1 (https=) |
| MX (2) | MX385999B (https=) |
| NZ (1) | NZ715905A (https=) |
| SG (2) | SG10201710538XA (https=) |
| WO (1) | WO2014205142A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201506312TA (en) | 2013-02-12 | 2015-09-29 | Replicel Life Sciences Inc | Compositions and methods for treating and repairing tendons |
| WO2015123477A1 (en) | 2014-02-12 | 2015-08-20 | Replicel Life Sciences Inc. | Compositions and methods for treating bone, joints and cartilage |
| DE102015119880B4 (de) * | 2015-11-17 | 2018-05-24 | Technische Universität Berlin | Verfahren zur Herstellung von Haarfollikeln und de novo Papillen sowie deren Verwendung für in vitro Tests und in vivo Implantate |
| WO2017118979A1 (en) * | 2016-01-07 | 2017-07-13 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Compositions and methods for generating immunotolerant responses |
| CN108865975B (zh) * | 2018-07-16 | 2021-11-23 | 浙江普罗亭健康科技有限公司 | 斑块组织消化试剂盒及其应用 |
| CN111647550A (zh) * | 2020-05-08 | 2020-09-11 | 嘉禾弘生(深圳)健康产业集团有限公司 | 一种组织块酶联合法培养人皮肤成纤维细胞的方法 |
| WO2022071459A1 (ja) * | 2020-09-30 | 2022-04-07 | テルモ株式会社 | 老化細胞判定システム |
| CN119331808A (zh) * | 2024-12-19 | 2025-01-21 | 包头市中心医院 | 一种将小鼠皮肤组织快速消化为单细胞的方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995001423A1 (en) * | 1993-07-01 | 1995-01-12 | The Trustees Of The University Of Pennsylvania | Methods of culturing and modulating the growth of hair follicular stem cells |
| EP0980270A1 (en) * | 1997-04-30 | 2000-02-23 | University Of Durham | Dermal sheath tissue in wound healing |
| US20040057937A1 (en) * | 1997-04-30 | 2004-03-25 | Jahoda Amanda Jane | Dermal sheath tissue in wound healing |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925964D0 (en) * | 1999-11-03 | 1999-12-29 | Jahoda Colin A B | Hair transplantation |
| KR100616752B1 (ko) * | 2004-11-29 | 2006-08-31 | 박정극 | 모낭 유도 능력이 있는 모유두 조직의 제조방법 |
| US8206980B2 (en) * | 2005-09-30 | 2012-06-26 | Phoenixbio Co., Ltd. | Method for cultivation of hair follicular dermal sheath cells |
| CN101410508B (zh) * | 2006-01-27 | 2013-07-03 | 加利福尼亚大学董事会 | 仿生支架 |
| BRPI1011999A2 (pt) * | 2009-06-05 | 2017-06-27 | Skinrephair Ltd | "uso de células-tronco de bainhas radiculares do cabelo e células precursoras de queratinócitos para a regeneração de pele envelhecida" |
| KR102025636B1 (ko) * | 2011-10-27 | 2019-11-04 | 우니베르지태트 라이치히 | 모낭 외모낭초로부터 멜라닌세포를 유도하기 위한 방법 및 이식을 위한 제조 |
| SG11201506312TA (en) * | 2013-02-12 | 2015-09-29 | Replicel Life Sciences Inc | Compositions and methods for treating and repairing tendons |
-
2014
- 2014-06-18 CA CA2919091A patent/CA2919091A1/en active Pending
- 2014-06-18 AU AU2014281515A patent/AU2014281515B2/en not_active Ceased
- 2014-06-18 SG SG10201710538XA patent/SG10201710538XA/en unknown
- 2014-06-18 EP EP14737128.0A patent/EP3010515A1/en not_active Withdrawn
- 2014-06-18 JP JP2016521558A patent/JP6594301B2/ja not_active Expired - Fee Related
- 2014-06-18 CN CN202310304734.8A patent/CN116716242A/zh active Pending
- 2014-06-18 KR KR1020217028357A patent/KR20210114545A/ko not_active Ceased
- 2014-06-18 US US14/900,105 patent/US20160136206A1/en not_active Abandoned
- 2014-06-18 SG SG11201510300RA patent/SG11201510300RA/en unknown
- 2014-06-18 CN CN201480043963.8A patent/CN105611937A/zh active Pending
- 2014-06-18 BR BR112015031772-3A patent/BR112015031772B1/pt not_active IP Right Cessation
- 2014-06-18 NZ NZ715905A patent/NZ715905A/en not_active IP Right Cessation
- 2014-06-18 WO PCT/US2014/043048 patent/WO2014205142A1/en not_active Ceased
- 2014-06-18 MX MX2015017095A patent/MX385999B/es unknown
- 2014-06-18 KR KR1020167001386A patent/KR20160048056A/ko not_active Ceased
-
2015
- 2015-12-11 MX MX2021010546A patent/MX2021010546A/es unknown
-
2019
- 2019-09-24 JP JP2019172492A patent/JP2020075907A/ja active Pending
-
2020
- 2020-06-25 US US16/912,565 patent/US20210106628A1/en not_active Abandoned
-
2021
- 2021-10-07 JP JP2021165694A patent/JP2022008966A/ja active Pending
-
2023
- 2023-09-29 JP JP2023169606A patent/JP2023174721A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995001423A1 (en) * | 1993-07-01 | 1995-01-12 | The Trustees Of The University Of Pennsylvania | Methods of culturing and modulating the growth of hair follicular stem cells |
| EP0980270A1 (en) * | 1997-04-30 | 2000-02-23 | University Of Durham | Dermal sheath tissue in wound healing |
| US20040057937A1 (en) * | 1997-04-30 | 2004-03-25 | Jahoda Amanda Jane | Dermal sheath tissue in wound healing |
Non-Patent Citations (2)
| Title |
|---|
| J. Invest. Dermatol., 2003, Vol.121, p.1267-1275 * |
| Jahoda et al., Hair follicle dermal cells differentiate into adipogenic and osteogenic lineages, Experimental Dermatology, vol. 12, no. 6 10 December 2003 (abstract). * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116716242A (zh) | 2023-09-08 |
| SG11201510300RA (en) | 2016-01-28 |
| JP2020075907A (ja) | 2020-05-21 |
| JP2022008966A (ja) | 2022-01-14 |
| US20210106628A1 (en) | 2021-04-15 |
| MX2021010546A (es) | 2021-10-01 |
| CA2919091A1 (en) | 2014-12-24 |
| MX385999B (es) | 2025-03-18 |
| MX2015017095A (es) | 2016-04-06 |
| KR20210114545A (ko) | 2021-09-23 |
| SG10201710538XA (en) | 2018-01-30 |
| AU2014281515A1 (en) | 2016-02-04 |
| BR112015031772A2 (pt) | 2017-07-25 |
| BR112015031772B1 (pt) | 2021-09-08 |
| US20160136206A1 (en) | 2016-05-19 |
| JP2023174721A (ja) | 2023-12-08 |
| NZ715905A (en) | 2021-12-24 |
| CN105611937A (zh) | 2016-05-25 |
| KR20160048056A (ko) | 2016-05-03 |
| JP6594301B2 (ja) | 2019-10-23 |
| JP2016523254A (ja) | 2016-08-08 |
| EP3010515A1 (en) | 2016-04-27 |
| WO2014205142A1 (en) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210106628A1 (en) | Compositions and methods for treating skin | |
| JP6970718B2 (ja) | 腱の治療及び修復用組成物及び方法 | |
| US20170165299A1 (en) | Compositions and methods relating to treatments of the oral cavity | |
| US10500233B2 (en) | Compositions and methods for treating bone, joints and cartilage | |
| HK40006994A (en) | Methods for isolating non-bulbar dermal sheath cells and compositions | |
| NZ711563B2 (en) | Compositions and methods for treating and repairing tendons | |
| NZ750474A (en) | Compositions and methods for treating and repairing tendons | |
| NZ750474B2 (en) | Compositions and methods for treating and repairing tendons |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |